PSMA-11

Phase 2Small molecule

NNational Cancer Institute (NCI)

PSMA-11 is one of 8 small molecule programs targeting Prostate Neoplasms. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate NeoplasmsActive, not recruiting

Magnetic Resonance ImagingCompleted

Prostate NeoplasmsPhase 2

Active, not recruiting

Magnetic Resonance ImagingPreclinical

Completed

Competition

Competitive Landscape

9 competitors in Magnetic Resonance Imaging

#DrugCompanyPhaseTrials

Elucirem

GGuerbet

Approved

1 2

Minipress

Pfizer

Phase 2

2 3

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Phase 1

1 4

PSMA-11

NNational Cancer Institute (NCI)

Phase 2

1 5

D-Cycloserine

MMassachusetts General Hospital

Preclinical

1 6

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

PSMA-1007

AABX advanced biochemical compounds GmbH

Preclinical

1 8

GLP-1 Agonists

MMedical College of Wisconsin

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 2Active, not recruiting

Prostate Neoplasms

NCT03181867

Clinical

Trials by Indication[1]

mCRPC1 trial

177Lu-PSMA-617 Managed Access Program for mCRPC Patients

No longer available·AAdvanced Accelerator Applications··NCT04825652

Magnetic Resonance Imaging1 trial

Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA

Completed·IIrene Burger·N/A·NCT03187990·52 enrolled

Prostate Neoplasms1 trial

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03181867·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PSMA-11. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PSMA-11 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PSMA-11. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

PSMA-11

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

mCRPC1 trial

Magnetic Resonance Imaging1 trial

Prostate Neoplasms1 trial

References

Drug Info

Quick Facts

Related News